• 1. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 2. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 3. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides

Comprehensive Overview of 4-METHYL-3-(MORPHOLINE-4-SULFONYL)BENZOIC ACID (CAS No. 300383-08-8): Properties, Applications, and Industry Insights

4-METHYL-3-(MORPHOLINE-4-SULFONYL)BENZOIC ACID (CAS No. 300383-08-8) is a specialized organic compound that has garnered significant attention in pharmaceutical and chemical research. This sulfonamide derivative features a unique molecular structure combining a benzoic acid core with a morpholine sulfonyl moiety, making it valuable for drug discovery and material science applications. Its chemical stability and bioavailability properties align with current industry demands for novel intermediates in small molecule therapeutics.

Recent studies highlight the compound’s role in modulating enzyme inhibition, particularly in targeting kinase pathways—a hot topic in oncology and metabolic disorder research. Researchers are exploring its potential as a scaffold molecule for designing selective inhibitors, addressing frequent search queries like "new kinase inhibitor candidates 2024" or "morpholine sulfonyl derivatives in drug design". The methyl-substituted aromatic ring enhances lipophilicity, a critical factor for blood-brain barrier penetration—an area of growing interest in neurodegenerative disease therapeutics.

From a synthetic chemistry perspective, 300383-08-8 exemplifies modern trends in green chemistry. Its preparation often involves catalytic sulfonylation methods, reducing hazardous byproducts—a response to the surge in searches for "sustainable synthetic routes for sulfonamides". Analytical characterization via HPLC-MS and NMR spectroscopy confirms its high purity (>98%), meeting stringent requirements for pharmaceutical intermediates.

The compound’s structure-activity relationship (SAR) has become a focal point in medicinal chemistry forums. Computational modeling suggests the morpholine sulfonyl group contributes to hydrogen bonding interactions with biological targets, explaining its prevalence in studies related to "GPCR modulator development". This aligns with patent analyses showing increased filings for sulfonamide-containing drugs between 2020-2024.

Industrial applications of 4-METHYL-3-(MORPHOLINE-4-SULFONYL)BENZOIC ACID extend to advanced material synthesis. Its dual hydrophilic-lipophilic balance (HLB) makes it suitable for designing polymeric carriers in controlled drug delivery systems—a trending topic in "smart biomaterials 2024" discussions. Supply chain data indicates rising demand from contract research organizations (CROs) specializing in preclinical development.

Quality control protocols for CAS 300383-08-8 emphasize ICH guidelines, particularly for genotoxic impurity testing. This responds to regulatory shifts reflected in searches like "FDA sulfonamide impurity limits". Storage recommendations typically specify ambient temperature protection from moisture, with stability studies confirming 24-month shelf life under proper conditions.

Emerging research explores the compound’s utility in proteolysis targeting chimeras (PROTACs), connecting to the booming interest in "targeted protein degradation technologies". The benzoic acid moiety serves as an anchor for E3 ligase recruitment, while the morpholine sulfonyl segment enables target protein binding—demonstrating structural versatility that satisfies multiple drug discovery paradigms simultaneously.

• 10252-82-1(4-(morpholine-4-sulfonyl)benzoic acid)
• 87223-34-5(2-(morpholine-4-sulfonyl)benzoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)